当前位置：易推广 > 上海陶术生物科技有限公司 > 产品展示
企业档案
会员类型：会员
已获得易推广信誉 等级评定
(0 -40)基础信誉积累，可浏览访问
(41-90)良好信誉积累，可接洽商谈
(91+ )优质信誉积累，可持续信赖
易推广会员：5年
工商认证 【已认证】
最后认证时间：
注册号： 【已认证】
法人代表： 【已认证】
企业类型：生产商 【已认证】
注册资金：人民币万 【已认证】
产品数：86101
参观次数：3497462
自主品牌
已选条件
-
T76806Bezlotoxumab；化合物 BezlotoxumabBezlotoxumab
Bezlotoxumab, a human monoclonal antibody, targets and binds to Clostridium difficile (C. difficile) toxin B, thereby inhibiting its ability to damage intestinal epithelium and cause colitis [1].
价 格：￥电议型 号：T76806产 地：中国大陆
-
T76805Epratuzumab；化合物 EpratuzumabEpratuzumab
Epratuzumab (Antibody hLL 2), an anti-CD22 IgG1 monoclonal antibody, serves as both a tumor-imaging and immunomodulatory agent. It induces CD22 phosphorylation and has been employed in researching Non-Hodgkin’s Lymphomas (NHL) and select autoimmune diseases [1].
价 格：￥电议型 号：T76805产 地：中国大陆
-
T76803Elsilimomab；化合物 ElsilimomabElsilimomab
Elsilimomab (B-E8), an IgG1 monoclonal antibody targeting interleukin-6 (IL-6), exhibits a dissociation constant (K D) of 22 pM and an inhibitory concentration (IC 50) of 1.4 nM. It is applicable in researching multiple myeloma, renal cell carcinoma, and rheumatoid arthritis (RA) [1] [2] [3].
价 格：￥电议型 号：T76803产 地：中国大陆
-
T76802Drozitumab；化合物 DrozitumabDrozitumab
Drozitumab (PRO 95780) is an agonistic human monoclonal antibody targeting the death receptor DR5. It demonstrates significant antitumor efficacy against rhabdomyosarcoma [1] [2] [3].
价 格：￥电议型 号：T76802产 地：中国大陆
-
T76801Denintuzumab；化合物 DenintuzumabDenintuzumab
Denintuzumab (hBU 12), a recombinant humanized anti-CD19 monoclonal antibody, serves as the antibody component in the synthesis of antibody-drug conjugates (ADC), notably Denintuzumab Mafodotin (SGN-CD19A). This ADC is utilized in the research of acute lymphoblastic leukemia [1].
价 格：￥电议型 号：T76801产 地：中国大陆
-
T76800Dalotuzumab；化合物 DalotuzumabDalotuzumab
Dalotuzumab (MK-0646) is a humanized recombinant monoclonal antibody (IgG1 type) that targets IGF-1R, inhibiting tumor cell proliferation, IGF-1R autophosphorylation, and Akt phosphorylation mediated by IGF-1 and IGF-2. It further induces apoptosis and cell cycle arrest. When used alongside other anticancer agents like statins, Dalotuzumab´s antitumor activity is significantly enhanced both in vitro and in vivo [1] [2] [3].
价 格：￥电议型 号：T76800产 地：中国大陆
-
T76799Citatuzumab bogatox；化合物 Citatuzumab bogatoxCitatuzumab bogatox
Citatuzumab bogatox (VB6-845) is a recombinant immunotoxin consisting of a humanized antibody´s Fab fragment targeting EpCAM and a modified bouganin cytotoxin. It selectively binds to EpCAM-positive cell lines, inducing apoptosis, and demonstrates efficacy in EpCAM-positive human tumor xenograft models [1] [2] [3].
价 格：￥电议型 号：T76799产 地：中国大陆
-
T76798Bimekizumab；化合物 BimekizumabBimekizumab
Bimekizumab (Anti-Human IL17A/IL-17F Recombinant Antibody), a humanized monoclonal antibody, selectively neutralizes IL-17A and IL-17F, both of which promote osteogenic differentiation in human periosteum-derived cells (hPDC). Consequently, Bimekizumab inhibits inflammation-driven osteogenic differentiation [1].
价 格：￥电议型 号：T76798产 地：中国大陆
-
T76796Patritumab；帕曲妥单抗U3-1287|||AMG-888；U3-1287|||AMG-888
Patritumab (U3-1287) is an anti-HER3 monoclonal antibody with potential antitumor activity and inhibits phosphorylation of EGFR, HER2, HER3, ERK, and AKT.Patritumab promotes apoptosis and inhibits proliferation in non-small cell lung cancer.
价 格：￥电议型 号：T76796产 地：中国大陆
-
T76795Xentuzumab；珍妥珠单抗BI 836845；BI 836845
Xentuzumab (BI836845) is a recombinant monoclonal antibody to humanised IGF ligand that inhibits IGF1 and IGF2 growth-promoting signalling and inhibits AKT activation for the study of solid tumours.
价 格：￥电议型 号：T76795产 地：中国大陆
-
T76794Ulocuplumab；乌洛鲁单抗BMS 936564|||MDX 1338；BMS 936564|||MDX 1338
Ulocuplumab (BMS-936564) is a fully human anti-CXCR4 IgG4 antibody.Ulocplumab exhibits antitumor activity in acute myeloid leukemia (AML), non-Hodgkin´s lymphoma (NHL), and multiple myeloma transplantation models.Ulocplumab inhibits the migration of chronic lymphocytic leukemia (CLL) cells under CXCR4 activation, induces apoptosis, and inhibits the growth and migration of cancer cells. Ulocplumab inhibits CXCL12-mediated chronic lymphocytic leukemia (CLL) cell migration in response to CXCR
价 格：￥电议型 号：T76794产 地：中国大陆
-
T76793Tigatuzumab；化合物 TigatuzumabTigatuzumab
Tigatuzumab (CS-1008), a humanized IgG1 monoclonal antibody, specifically targets death receptor 5 (DR5), inducing apoptosis in cancer cells and inhibiting tumor growth in vivo. It holds potential for cancer research applications [1].
价 格：￥电议型 号：T76793产 地：中国大陆
-
T76792Sibrotuzumab西罗珠单抗BIBH 1|||Anti-Human FAP Recombinant Antibody
Sibrotuzumab (BIBH 1) is a humanized IgG1 monoclonal antibody targeting Fibroblast Activating Protein (FAP).Sibrotuzumab is used in the study of colorectal cancer and non-small cell lung cancer.
价 格：￥电议型 号：T76792产 地：中国大陆
-
T76791Seribantumab；化合物 SeribantumabSeribantumab
Seribantumab (MM 121), a fully human IgG2 monoclonal antibody, specifically targets HER3, inhibiting the activation of the epidermal growth factor receptor (ErbB) family and its subsequent signaling. This action effectively blocks neuregulin 1 (NRG1) fusion-dependent tumorigenesis within in vitro and in vivo studies of patient-derived cancer models in breast, lung, and ovarian cancers [1].
价 格：￥电议型 号：T76791产 地：中国大陆
-
T76790Inotuzumab；英妥珠单抗Inotuzumab
Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) is a humanized IgG4 antibody targeting CD22. Inotuzumab is a naked antibody to Inotuzumab ozogamicin and can be used to synthesize antibody-active molecule conjugators (Inotuzumab ozogamicin). Inotuzumab can be used to study acute lymphoblastic leukemia and non-Hodgkin´s lymphoma.
价 格：￥电议型 号：T76790产 地：中国大陆
-
T76789Imalumab；化合物 ImalumabImalumab
Imalumab (BAX69), a recombinant human IgG1 monoclonal antibody, specifically targets macrophage inhibitory factor (MIF). It is utilized in the research of ovarian carcinoma, recurrent malignant ascites, and cancer [1].
价 格：￥电议型 号：T76789产 地：中国大陆
-
T76788Demcizumab登赛珠单抗OMP 21M18
Demcizumab (OMP 21M18) is an anti-DLL4 monoclonal antibody. Demcizumab is a potent Notch pathway inhibitor. Demcizumab is effective in multiple cancer models, both alone and in combination with chemotherapy agents.
价 格：￥电议型 号：T76788产 地：中国大陆
-
T76787Conatumumab；西他土珠TRAIL-R2 mAb|||AMG 655；TRAIL-R2 mAb|||AMG 655
Conatumumab (AMG 655) is a monoclonal agonist antibody targeting human death receptor 5 (DR5, TRAILR2) at Kd 1 nM for long DR5 and Kd 0.8 nM for short DR5. Conatumumab induces apoptosis in a variety of tumor types through caspase activation. Conatumumab can be used to study advanced solid tumors.
价 格：￥电议型 号：T76787产 地：中国大陆
-
T76786Cabiralizumab；化合物 CabiralizumabCabiralizumab
Cabiralizumab (FPA 008), an anti-CSF1R monoclonal antibody (MAb), promotes T cell infiltration and boosts antitumor immune responses. It also prevents osteoclast activation, thereby inhibiting bone destruction, and is utilized in rheumatoid arthritis (RA) research. Additionally, Cabiralizumab can be paired with Nivolumab in lung cancer studies [1] [2].
价 格：￥电议型 号：T76786产 地：中国大陆
-
T76785Brontictuzumab；化合物 BrontictuzumabBrontictuzumab
Brontictuzumab (OMP 52M51), a monoclonal antibody (MAb), selectively targets and binds to the negative regulatory region of Notch1, inhibiting its signaling. This action inhibits tumor cell proliferation, rendering Brontictuzumab a potential therapeutic agent for leukemia and lymphoma research [1] [2] [3].
价 格：￥电议型 号：T76785产 地：中国大陆
